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Abstract: Physical activity (PA) reduces the risk of cognitive decline (CD) in the general population.
However, little is known about whether the presence of the apolipoprotein E epsilon 4 allele (APOE e4)
could modify this beneficial effect. The aim of this systematic review was to analyze and synthetize
the scientific evidence related to PA levels and CD risk in cognitively healthy APOE e4 carriers.
Four electronic databases were analyzed. Only original articles with longitudinal study design were
selected to analyze the relationship between PA and CD in APOE e4 carriers. Five studies were
included in the systematic review. All studies except one stated that PA is a protective factor against
CD in APOE e4 carriers. Moreover, partial support was found for the hypothesis that a greater
amount and intensity of PA are more beneficial in CD prevention. The results support the idea that
PA is a protective factor against CD in APOE e4 carriers. Nevertheless, it would be necessary to carry
out further studies that would allow these findings to be contrasted.
Keywords: exercise; APOE e4; Cognitive Dysfunction; mild cognitive impairment
1. Introduction
Cognitive decline (CD) in older adults is an ever-growing problem because the number
of older adults is increasing [1] and because longer life increases the likelihood of loss of
memory and decline in the performance of cognitive tasks [2,3]. Cognitive performance
is considered an important aspect of healthy aging [4]. There is an increasing interest in
this subject, which is now a priority in public health [5], and the European Innovation
Partnership on Active and Health Aging [6], has also recognized its relevance. Therefore,
the prevention of CD should be an area of increasing interest for research in public health.
Mild cognitive impairment (MCI) is one construct of CD that has received considerable
attention in the literature, mainly because it has been widely sustained that MCI progresses
to dementia, Alzheimer’s disease in particular, in a high proportion of individuals [7], and
also because of its high prevalence, even in the community. Several studies have suggested
the idea that CD, which includes MCI, may be considered a health index because both
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have been associated with an increased mortality rate in the general population [8–10].
Moreover, it has been shown that CD is associated with disability in the general population,
even after controlling for dementia [11]. Consequently, the prevention of CD should be a
subject of particular attention.
A multitude of risk factors of different typology have been associated with CD [2,12,13];
age is the most important one [3], although cardiovascular diseases are also risk fac-
tors [2,12,14]. Other characteristics such as low educational level [12], depression and
anxiety [10,15,16], vitamin B12 or D deficiency [12] as well as certain lifestyles that include
smoking and physical inactivity [14] may also play a role in CD.
Among the previously documented risk factors of CD, a major genetic risk factor
is the presence of the apolipoprotein E epsilon 4 allele (APOE e4) [2,17]. The human
apolipoprotein E gene is polymorphic, presenting three alleles: epsilon 3 (e3), epsilon
2 (e2) and epsilon 4 (e4). The e3 variant is the most frequent allele (~77% in the gen-
eral population), while e2 and e4 are less common, with occurrence rates of 7.8% and
15.1%, respectively [18]. APOE e4 presence is associated with several risk factors and
diseases [19–22], including faster CD [2,23]. Homozygotes have the highest risk, followed
by heterozygotes, implying that the effect of APOE e4 on CD is dose-dependent [17,24].
The underlying mechanisms by which APOE e4 is associated with early CD suggest that
APOE e4 is deficient in beta-amyloid clearance and accelerates beta-amyloid deposition
to form amyloid plaques in the brain [20]. The toxic amyloid plaques injure synapses and
ultimately cause neurodegeneration and CD [25].
On the other hand, protective factors of CD have also been reported [12,14,26], includ-
ing intellectual activity and lifestyles aspects such as social interaction and physical activity
(PA) [27,28]. PA may act on several risk factors related to CD, and a relationship between PA
and neurogenesis, plasticity and higher white matter volume has been shown [29–31]. Sev-
eral studies demonstrate how cardiovascular diseases and their risk factors are associated
with CD and lower performance in multiple cognitive domains [32,33]. However, PA is
beneficial in the prevention of cardiovascular diseases and their risk factors [34–36], as well
as other known risk factors for CD such as depression or anxiety [35,37]. Therefore, PA may
indirectly prevent CD by counteracting the CD risk factors. It has also been reported that
PA is beneficial for the prevention of MCI and CD in the general population [12,29,31,38,39].
Recent meta-analyses also suggest that PA reduces the risk of suffering CD [27,40]; how-
ever, none of the studies reviewed were differentiated according to the genotyping of the
participants based on the presence of APOE e4. This is a source of concern, since perhaps
the effect of PA in subjects with high genetic risk of CD, APOE e4 carriers, is different from
the effect that PA has in subjects without genetic risk, APOE e4 non-carriers. In order to
create useful strategies for the prevention of severe neurodegenerative diseases, it is crucial
to investigate the role that PA may have against neurodegeneration in these subjects with
increased genetic risk.
Some studies have analyzed to what extent the amount and intensity of PA influence
its potential beneficial effect for the prevention of CD in the general population. Several
studies have suggested that higher levels of PA (exercise engaged in ≥3 days/week at
intensity greater than walking) or vigorous intensity PA is more beneficial [41–44], but
discrepant results have also been reported [40], and the question is not settled.
On the basis of the previous reports, the main aim of this systematic review was
to analyze and synthetize the scientific evidence related to PA levels and CD risk in
cognitively healthy APOE e4 subjects (without previous CD) and to review the literature
that investigates whether the effect of PA in these subjects is directly associated with
amount and intensity.
2. Materials and Methods
This work used the model of preferred reporting items for a systematic review and
meta-analysis (PRISMA) [45] to ensure accuracy and comprehensiveness. A review protocol
was written prior to reviewing the literature.
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As all analyses were based on publicly available summary statistics, no ethical ap-
proval from an institutional review board or informed patient consent was required.
Four electronic databases were analyzed systematically using different keywords and
Boolean operators. The databases analyzed were PubMed, SportDiscus, Cochrane Library
and Web of Science (WOS). The strategy included searching by index terms (MeSH) and
by free text. The search by index terms used in PubMed was: “Exercise” [Mesh] AND
“Cognitive Dysfunction” [Mesh] AND “Apolipoprotein E4” [Mesh]. The search by free text
used in PubMed, SportDiscus, Cochrane Library and WOS was: (“Physical Activity” OR
“Exercise”) AND (“Memory impairment” OR “Age-associated memory impairment” OR
“Late-life forgetfulness” OR “age-related cognitive decline” OR “Mild Cognitive Impair-
ment” OR “Cognitive Decline” OR “Cognitive Dysfunction”) AND (“Apolipoprotein E4”
OR “Apoe4” OR “Apo E4” OR “Apoe 4” OR “Apoe epsilon 4” OR “Apolipoprotein E-4”
OR “Apo E-4” OR “Apo E 4” OR “Apolipoprotein E epsilon4”).
For the present systematic review, only original articles published up to 13 April 2021
were analyzed, excluding all types of symposium reports, letters to the editor, conference
abstracts, books, opinions of experts and reviews of any kind. The inclusion criteria used
were that the studies covered the theme of the present review (relationship between the
risk of CD (which includes cases of MCI), and PA in participants genotyped with e4 allele),
were longitudinal studies, used humans as participants, were published in English and
that the sample used was composed of people without brain injuries or diagnosed mental
disorders at baseline.
Studies were excluded if they did not provide information on how the cognitive
function or the PA was evaluated, if the PA was evaluated jointly with the rest of the
activities carried out in the free time (including sedentary leisure activities) or if they were
related to dementia and not specifically to CD. Papers that did not specifically assess the
impact of PA on CD in APOE e4 and those related to animal experimentation were all
excluded.
Applying these criteria and using the search strategy described, the process of article
selection is illustrated in Figure 1.
Two reviewers (J.L.P.-L. and A.G.A.) carried out the selection process independently
based on the criteria previously established. Any discrepancies were resolved by consensus,
and in some cases, a third reviewer (J.A.C.) was consulted to resolve disagreements. Starting
from the initial search after applying the search criteria and strategies, the articles were first
selected based on the title and abstract, identifying key and thematic keywords related or
unrelated to our aim, then those duplicated articles were eliminated, and the last screening
was performed after a complete and exhaustive reading of the full text, selecting the papers
to be included in our systematic review. Finally, after the article selection process, the
bibliography of the articles was reviewed in order to identify articles that could meet our
inclusion criteria.
Data from the studies, such as the longitudinal follow-up time, the population sample
used and its characteristics (average age of the participants in the baseline, sex and geno-
type), the cognitive function and PA evaluation method, the covariates (confounders) used
in the studies, the study design and the main results, were extracted based on a second
reading of the full text of the articles included in the systematic review. Moreover, the
results of the included studies were grouped according to whether they compared the
risk for CD among different PA levels only in e4 carriers or in e4 carriers vs. non-carriers.
Participants of the studies were considered APOE e4 carriers if they carried at least one
e4 allele.
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hort studies [46] and the PEDro scale for randomized controlled trials [47]. The NOS for 
cohort studies uses a “star” rating system to judge quality based on three aspects of the 
study: (a) selection of participants, (b) comparability of study groups and (c) outcome of 
interest. The maximum number of stars a study may receive in each of these three catego-
ries is 4, 2 and 3, respectively. The highest rating a study can receive is 9 stars. A detailed 
description of the NOS criteria for assessing quality can be found in the Supplementary 
Materials. 
The PEDro scale consists of 11 criteria that assess the methodological quality of the 
experimental studies based on three aspects: internal validity (criteria 2–9), interpretabil-
ity (criteria 10–11) and external validity or applicability (criterion 1).  
In the NOS, we assigned scores of 0–3, 4–6 and 7–9 to indicate low, moderate and 
high-quality studies, respectively, and, in the PEDro scale, we assigned scores of 0–4, 5–8, 
and 9–11 to indicate low, moderate and high-quality studies, respectively. 
3. Results 
3.1. Study Selection 
As shown in Figure 1, the initial electronic database search yielded 464 hits in total. 
A total of 411 articles were excluded following screening titles and abstracts, 11 articles 
were removed for duplicates and 37 articles were excluded following screening of full 
texts. A total of five articles from the electronic search met the inclusion criteria, and, after 
the manual search, no articles were added. 
3.2. Description of Included Studies 
There are several differences in the design and the methodology of the different in-
cluded studies. Four of them have a prospective cohort design [48–51], and the other is a 
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WOS—Web of Science.
Quality assessment was performed using the Newcastle–Ottawa Scale (NOS) for
cohort studies [46] and the PEDro scale for randomized controlled trials [47]. The NOS
for cohort studies uses a “star” rating system to judge quality based on three aspects of
the study: (a) s lection of participants, (b) comparability of study groups and (c) out-
come of interest. The maximum number of stars a study may receive in each of these
three categories is 4, 2 and 3, respectively. The highest rating a study can receive is 9
stars. A d tailed description of the NOS criteria for assessing uality can e found in the
Supplementary Materials.
The PEDro scale consists of 11 criteria that assess the methodological quality of the
experimental studies based on three aspects: internal validity (criteria 2–9), interpretability
(criteria 10–11) and external validity or applicability (criterion 1).
In the NOS, we assigned scores of 0–3, 4–6 and 7–9 to indicate low, moderate and
high-quality studies, respectively, and, in the PEDro scale, we assigned scores of 0–4, 5–8,
and 9–11 to indicate low, moderate and high-quality studies, respectively.
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3. Results
3.1. Study Selection
As shown in Figure 1, the initial electronic database search yielded 464 hits in total.
A total of 411 articles were excluded following screening titles and abstracts, 11 articles
were removed for duplicates and 37 articles were excluded following screening of full texts.
A total of five articles from the electronic search met the inclusion criteria, and, after the
manual search, no articles were added.
3.2. Description of Included Studies
There are several differences in the design and the methodology of the different
included studies. Four of them have a prospective cohort design [48–51], and the other is a
randomized controlled trial [52]. Between-study differences were observed in the methods
to assess the exposure and outcome. Moreover, the range of follow-up time among the
studies is quite broad, from 18 months [51] to 10 years [52].
Several studies were carried out on Americans [48,50,52], one on Mexican-Americans [50]
and another on American populations of Indian, African, Asian and Hispanic descent [52].
In the latter study, it should be noted that all the participants in the baseline had type II
diabetes and overweight or obesity [52]. Another study was conducted on Caucasians [51],
and the last one was carried out on Asians [49].
Regarding all the participants of the studies that compared the risk for CD among
different PA levels in e4 carriers vs. non-carriers (Table 1), a total of 7148 participants
were included, and 1425 of them were APOE e4 carriers, 5043 were non-carriers and the
remaining 680 were reported as having a missing or unknown genotype (nine study partic-
ipants from one article [48], and 671 study participants from another [52]). Moreover, the
population sample of the studies ranged from 78 participants [51] to 3802 participants [52].
Taking into account all the participants of the studies that compared the risk for
CD among different PA levels in e4 carriers (Table 2), a total of 792 participants were
included, but the samples of the studies also varied between 26 participants [51] and
474 participants [48].
3.3. Assessment of Main Variables
To assess PA, different types of questionnaires were used. Two of the studies used
questionnaires created ad hoc that were not validated [49,50], while the others used vali-
dated questionnaires such as the Minnesota Leisure Time Physical Activity Questionnaire
and the 1985 National Health Interview Survey [48], Paffenbarger Physical Activity Ques-
tionnaire [52] or the Stanford Brief Activity Survey [51].
To assess cognitive function, all the studies used specific tests or questionnaires, and
although there is considerable diversity, in all the studies except one [48], the Mini-Mental
State Examination (MMSE) [49,51], or its modified version, the Modified Mini-Mental State
Examination (3MSE) [50,52], were used, both of which are employed worldwide [53].
Tables 1 and 2 show the questionnaire used in each of the studies to assess PA, cognitive
function and the criteria for establishing CD or MCI based on the cognitive assessment
tests used throughout the follow-up. Three of the included studies used MMSE or 3MSE
cutoff points to define CD [49,50,52], another used Petersen’s criteria for MCI [48] and the
remaining study used cutoff points in at least one of the principal outcome indices (DRS-2
and RAVLT) [51]. Tables 1 and 2 display the different criteria used in each study to classify
the participants among the different PA levels.
3.4. Risk of Bias Assessment
There was a heterogeneous quality in the methodology of the included studies, since
two had high quality [48,50], and the others had moderate quality [49,51,52] (Table 3).
Int. J. Environ. Res. Public Health 2021, 18, 7238 6 of 15














































- Intervention: >175 min
PA/week brisk
walking
- Control: PA, diet and
social support
- Non-carriers control group OR = 1.00 (ref.
group)
- Carriers control group OR = NI
- Carriers intervention group OR = 0.84








- Minnesota leisure time
physical activity
questionnaire































- Non-carriers and not LPA:
HR = 1.00 (ref. group)
- Carriers and not LPA: HR = 1.32
(95%CI: 0.70, 2.50, p > 0.05)
- Carriers and LPA: HR = 0.97











- Non-carriers and not MPA:
HR = 1.00 (ref. group)
- Carriers and not MPA: HR =
2.07 (95%CI: 1.32, 3.26, p < 0.05)
- Carriers and MPA: HR = 1.53




- Non-carriers and not VPA:
HR = 1.00 (ref. group)
- Carriers and not VPA: HR = 1.84
(95%CI: 1.42, 2.39, p < 0.05)
- Carriers and VPA: HR = 1.32





- Non-carriers and not LPA:
HR = 1.00 (ref. group)
- Carriers and not LPA: HR = 2.03
(95%CI: 1.23, 3.35, p < 0.05)
- Carriers and LPA: HR = 1.35





- Non-carriers and not MPA:
HR = 1.00 (ref. group)
- Carriers and not MPA: HR =
1.89 (95%CI: 1.37, 2.61, p < 0.05)
- Carriers and MPA: HR = 1.43





- Non-carriers and not VPA:
HR = 1.00 (ref. group)
- Carriers and not VPA: HR = 1.90
(95%CI: 1.51, 2.40, p < 0.05)
- Carriers and VPA: HR = 1.18
(95%CI: 0.67, 2.07, p > 0.05)




























Shih, I. et al.
(observational) 6.5
- MET-h/week of 18
common activities for










than the 20th per-
centile/decreased


























- No APOE e4 and High PA: HR = 1.00 (ref.
group)
- No APOE e4 and Low PA: HR = 1.39 (95%CI:
0.94, 2.07, p > 0.05)
- APOE e4 and High PA: HR = 2.20 (95%CI:
1.29, 3.74, p < 0.05)
- APOE e4 and Low PA: HR = 3.44 (95%CI:
1.85, 6.39, p < 0.05)
























- Level of PA:
- Low: ≤2 d/week of
low intensity (does not
meet ACSM recom.)




- APOE e4 Low-PA demonstrated higher
probability of decline than No-APOE e4
Low-PA; APOE e4 High-PA and No-APOE
e4 High-PA (all p < 0.05)
- APOE e4 High-PA probability of CD was
not statistically different compared to
No-APOE e4 Low-PA and No-APOE e4
High-PA (p > 0.05)
78 57(73) 72.6 (5.0)
26
(1) 52
Abbreviations: n = sample size; y = years; NI = Not Informed; STMS = Short Test of Mental Status; WAIS-R = Wechsler Adult Intelligence Scale—Revised; WMS-R = Wechsler Memory Scale—Revised;
PA = Physical Activity; LPA = Light Physical Activity; MPA = Moderate Physical Activity; VPA = Vigorous Physical Activity; HR = Hazard Ratio; MET = Metabolic Equivalent; h = hours; d = days; min = minutes;
3MSE = Modified Mini Mental Status Examination; SEVLT = Spanish English Verbal Learning Test; SENAS = Spanish English Neuropsychological Assessment Scale; FAQ = Functional Assessment Questionnaire;
OR = Odds Ratio; MMSE = Mini Mental State Examination; GDS = Geriatric Depression Scale; MDRS-2 = Mattis Dementia Rating Scale-2; RAVLT = Rey Auditory Verbal Learning Test; SD = Standard Deviation;
ACSM = American College of Sports Medicine; recom. = recommendations.
Int. J. Environ. Res. Public Health 2021, 18, 7238 8 of 15








Method to Assess Cognitive
Function
Adjudication of












































- In late life
- Always
LPA
- Never LPA: HR = 1.00 (ref. group)
- Only LPA in midlife: HR = 0.80 (95%CI: 0.33, 1.98,
p > 0.05)
- Only LPA in late life: HR = 0.59 (95%CI: 0.19, 1.82,
p > 0.05)




- Never MPA: HR = 1.00 (ref. group)
- Only MPA in midlife: HR = 0.90 (95%CI: 0.52,
1.55, p > 0.05)
- Only MPA in late life: HR = 0.96 (95%CI: 0.43,
2.13, p > 0.05)
- Always MPA: HR = 0.68 (95%CI: 0.40, 1.14,
p > 0.05)
VPA
- Never VPA: HR = 1.00 (ref. group)
- Only VPA in midlife: HR = 0.87 (95%CI: 0.57, 1.33,
p > 0.05)
- Only VPA in late life: HR = 1.00 (95%CI: 0.40,
2.49, p > 0.05)
- -Always VPA: HR = 0.46 (95%CI: 0.22, 0.95,
p < 0.05)






active sports; tai chi
(not validated)
- MMSE

















- At least one PA:
- Yes
- No
- No-PA OR = 1.00 (ref. group)
- Yes-PA OR = 0.34 (95%CI: 0.17, 0.68, p < 0.05)
292
(NI) NI NI








≥1 SD reduction on at
least one of the
principal outcomes
indices (DRS-2, RAVLT





- Level of PA:








- Low-PA group demonstrated higher probability
of decline than High-PA group (p < 0.05)
26
(1) NI NI
Abbreviations: n = sample size; y = years; STMS = Short Test of Mental Status; WAIS-R = Wechsler Adult Intelligence Scale; WMS-R = Wechsler Memory Scale; PA = Physical Activity; LPA = Light Physical
Activity; MPA = Moderate Physical Activity; VPA = Vigorous Physical Activity; HR = Hazard Ratio; MET = Metabolic Equivalent; h = hours; d = days; min = minutes; 3MSE = Modified Mini Mental Status
Examination; SEVLT = Spanish English Verbal Learning Test; FAQ = Functional Assessment Questionnaire; OR = Odds Ratio; MMSE = Mini Mental State Examination; GDS = Geriatric Depression Scale; MDRS-2
= Mattis Dementia Rating Scale-2; RAVLT = Rey Auditory Verbal Learning Test; ACSM = American College of Sports Medicine; recom. = recommendations; NI = Not Informed.
Int. J. Environ. Res. Public Health 2021, 18, 7238 9 of 15
Table 3. Newcastle–Ottawa and PEDro Quality Assessment of the studies included in the systematic review.
Study
Quality Assessment of Cohort Studies with NOS
Selection Comparability Outcome NOS QS
1 2 3 4 5 6 7 8 9
Krell, J. et al. * * * * * * * 7
Niti, M. et al. * * * * * * 6
Shih, I. et al. * * * * * * * * 8
Woodard, J.L. et al. * * * * * 5
Study
Quality Assessment of RCT Studies with PEDro Scale
1 2 3 4 5 6 7 8 9 10 11 PEDroQS
Espeland, M. et al. * * * * * * * 7
Abbreviations: NOS = Newcastle–Ottawa Scale; QS = Quality Score; RCT = Randomized Controlled Trial; * = One point.
3.5. Risk of CD among Different PA Levels
Two tables summarize the results of the included studies. Table 1 compares the studies
that analyze the risk in APOE e4 carriers vs. non-carriers in relation to PA levels, and
Table 2 compares the studies that analyze the risk between carriers with different PA levels.
Regarding the results provided in Table 1, Shih et al. stated that those carrying APOE
e4 who accomplished more than 35 MET-hours/week had a 2.20-fold increased hazard
ratio (HR) (95%CI: 1.29, 3.74, p < 0.05), and those carrying APOE e4 who performed less
than 35 MET-hours/week had a 3.44-fold increased HR (95%CI: 1.85, 6.39, p < 0.05) of
developing cognitive impairment compared to persons who were not APOE e4 carriers
and who performed more than 35 MET-hours/week [50]. Krell-Roesch et al. stratified their
results based on the intensity of PA (light, moderate and vigorous) and also based on the
moment in life when PA was performed (midlife or late life). Based on this stratification,
no differences in MCI risk were found for light and vigorous PA performed in midlife
or late life between APOE e4 carriers and non-carriers (Table 1). Nevertheless, when
compared to APOE e4 non-carriers who did not perform moderate PA in midlife, APOE
e4 carriers who did not perform moderate PA in midlife had a 2.07-fold increased HR
for MCI (95%CI: 1.32, 3.26, p < 0.05), while APOE e4 carriers who performed moderate
PA in midlife had a 1.53-fold increased HR for MCI (95%CI: 1.10, 2.15, p < 0.05). When
compared to APOE e4 non-carriers who did not perform moderate PA in late life, APOE
e4 carriers who did not perform moderate PA in late life had a 1.89-fold increased HR for
MCI (95%CI: 1.37, 2.61, p < 0.05), and those APOE e4 carriers who performed moderate PA
in late life had a 1.43-fold increased HR for MCI (95%CI: 1.05, 2.95, p < 0.05) [48]. Woodard
et al. revealed that the predicted probability of CD for APOE e4 carriers who reported low
levels of PA (≤2 days/week of low intensity) was significantly higher (p = 0.006) compared
to APOE e4 non-carriers who reported low or high levels of PA (≤2 days/week of low
intensity, or ≥3 days/week of moderate to heavy intensity, respectively) [51]. The article
by Woodard et al. also shows that the predicted probability of CD for APOE e4 carriers who
reported high levels of PA was not statistically different from that for APOE e4 non-carriers
who reported low or high levels of PA (p > 0.05) [51]. Espeland et al. found that APOE
e4 carriers who were involved in the PA intervention group had reduced odds for CD
(OR = 0.84, 95%CI: 0.52, 1.36, p > 0.05) as compared with non-carriers belonging to the
control group [52].
Referring to the results provided in Table 2 that compare the risk of CD among APOE
e4 carriers who showed different PA levels, Woodard et al. revealed that the predicted
probability of CD for APOE e4 carriers who reported low levels of PA (≤2 days/week
of low intensity) was significantly higher (p = 0.006) compared to carriers who reported
high levels of PA (≥3 days/week of moderate to heavy intensity) [51]. Krell-Roesch et al.
stratified their results based on the intensity of the PA (light, moderate and vigorous) and
also based on the moment in life when PA was performed (never, only in midlife, only
in late life, or always in midlife and late life). Based on this stratification, no significant
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differences for suffering MCI were found among carriers who performed or who did
not perform light or moderate PA in different moments of their lifespan; however, those
carriers who had performed vigorous intensity activity in midlife and late life (always) had
lower risk of developing MCI in comparison with those who never performed vigorous
PA: HR = 0.46 (95%CI: 0.22, 0.95, p < 0.05) [48]. Niti et al. reported that participants who
performed at least one PA had 0.34 odds for CD (95%CI: 0.17, 0.68, p < 0.05) compared with
participants who did not perform any PA [49].
4. Discussion
In relation to the aims of this systematic review, the results support the notion that PA
is a protective factor against CD in APOE e4 carriers independently of the methodology
used to assess the PA or the criteria to establish CD and PA levels, since this is confirmed
by four of the five studies included in this systematic review. It is remarkable in this first
review of previous reports in the literature that PA was effective in preventing CD in
high-risk individuals such as APOE e4 carriers. However, there are several issues related to
the methodology of included studies that must be taken into account in the interpretation
of the results.
As can be seen in Tables 1 and 2, all the studies except one [51] showed results adjusted
by different confounders, the most common being age and educational level. However,
only two studies carried out a follow-up period >5 years [50,52]. Moreover, the short period
of follow-up in some cases, the >20% loss of participants, the self-reported PA and the fact
that the results were not adjusted by important confounders such as age, educational level
or cardiovascular risk factors could affect the results.
The methodology used to assess PA in the studies had some weaknesses, as the
researchers used questionnaires, which are based on self-reported PA and, therefore, may
over- or underestimate participants’ PA. Some advantages of this type of questionnaire in
studies such as those included in the present review are apparent, such as their simplicity,
low cost, and ease of administration in large samples in a short period of time [54]. There
is wide recognition that the choice of method may be a trade-off between accuracy level
and feasibility [55], but when the aim is establishing a dose–response relationship, the use
of motion sensors such as accelerometers would be important, although their use in large
population studies is less feasible and they are not 100% accurate [54,56,57].
In addition, as can be seen in Tables 1 and 2, the use of different questionnaires to assess
PA among studies, and the use of different cutoff points to define the different PA levels,
make it difficult to compare among studies. Moreover, the heterogeneity in the method
to assess cognitive function and in the definition and criteria used for establishing CD or
MCI also complicates the comparison among studies. Nevertheless, the comparability of
studies is supported to some extent because these criteria are commonly used in clinical
practice to confirm the presence of CD.
Furthermore, most of the included studies only specified if the participants were
APOE e4 carriers, and therefore cases, or were APOE e4 non-carriers, and therefore controls,
but did not specify whether there were any APOE e2 carriers in control groups. This could
be of interest, because, as evidence suggests, APOE e2 has been associated with a reduced
CD risk [58].
Despite these circumstances, all the included studies except one [52] support the
idea that PA is a beneficial factor in terms of CD. The absence of significant differences
in this study might be due to different reasons: first, the different type of sample used
compared to the rest of the included studies, since all the participants had type 2 diabetes
and overweight or obesity, and these are independent risk factors for CD [59] and can
be improved with PA. Second, the intervention in this study may not be long enough to
observe differences. Third, the results were only adjusted by age.
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4.1. Physical Activity Dose and Risk of CD
Regarding the results of the studies, this review found that some studies suggest that
an increased amount and/or intensity of PA is more effective in reducing the risk of CD for
APOE e4 carriers [48,50,51]. This finding may be explained with previous reports, which
suggest that higher levels of PA may be associated with mitigating the increased risk of
beta-amyloid deposition in APOE e4 carriers [60].
However, the sample size in studies such as the one by Woodard et al. was small [51],
and PA amount and intensity were only self-reported, such that the precision of the dose–
response relationships may be affected. Therefore, although this review finds some support
for the hypothesis that an increased amount and intensity of PA is more protective against
CD in APOE e4 carriers, the evidence is limited, and new research may be needed to
document the precise amount and intensity of PA to recommend in APOE e4 carriers.
It could be conceivable that previous studies in the general population, non-stratified
by APOE e4 status, might shed some light on this subject. According to several longitudinal
studies, exercise intensity might be more beneficial than duration regarding cognitive
function in the general population [41,42]. However, analyzing some studies that reported
results related to the amount and intensity of PA adequate for the prevention of CD in
the general population, contradictory results were found. While some studies suggest
that moderate intensity seems to be sufficient to show a beneficial effect, although higher
intensity is more effective [27,61], others stated that light intensity, such as a leisurely walk
after dinner, is better than vigorous PA for the prevention of MCI [48].
It could be thought that the optimal dose of PA for APOE e4 persons to prevent CD
should not be very different from that of APOE e4 non-carriers. However, according to
Shih et al., the same PA level in APOE e4 carriers and non-carriers results in a different risk
reduction in CD, obtaining greater benefits for non-carriers [50]. Therefore, it is possible
that carriers should perform more PA to reduce the risk to the same extent as non-carriers,
but, on the other hand, a study conducted by Schuit et al. reported that, when performing
the same PA level in both groups, APOE e4 carriers obtain greater risk reduction for CD
than non-carriers [62]. It is, therefore, apparent that new studies are required to determine
the appropriate dose of PA to recommend in preventing CD.
4.2. Strengths and Limitations
The major strength of this review, which used the PRISMA system, is that, to our
knowledge, it is the first systematic review focused on studies that stratify by apolipopro-
tein E genotype in relation to the association of PA and CD. Despite this, there are other
limitations that must be considered. First, there is a heterogeneous methodology among the
studies to assess the main variables and define the outcome. In the five included studies, a
total of six different questionnaires were used to assess the PA, and a total of five different
criteria were used to classify the participants in terms of PA levels; further, different criteria
to diagnose CD were used in the included studies. Second, as discussed above, there are
no studies that assess the PA with an objective method. Third, there are few studies in the
literature related to our topic that show results by subgroups based on PA levels and the
APOE e4 status of the participants, and studies such as the one by Woodard et al. were
carried out on small samples.
4.3. Future Recommendations
Although there is some evidence indicating that PA can be a protective factor against
CD in APOE e4 persons, future research will be needed in order to corroborate this. It
seems that the literature is mainly limited by the failure to present data separately for
APOE e4 carriers and non-carriers, and more studies that stratify in groups according to
the genotype and PA levels of the participants should, therefore, be conducted. It is also
important to perform studies that evaluate PA objectively by means of motion sensors such
as accelerometry, as, despite some limitations, it allows a more precise assessment of the
amount and intensity of PA. It would also be interesting to perform intervention studies,
Int. J. Environ. Res. Public Health 2021, 18, 7238 12 of 15
ideally RCTs, in APOE e4 persons in order to provide data on the amount and intensity
of PA that will be optimal for the prevention/slowdown of CD in this type of population.
Currently, some clinical trials such as U.S. POINTER, IGNITE and PAAD-2 [63–65] are
focused on the role that PA and other lifestyle variables have in cognition among different
types of population, including APOE e4 carriers. The results of these clinical trials could
shed some light on this area.
5. Conclusions
The results of the studies included in this systematic review support the idea that
PA is a protective factor against CD in individuals of high genetic risk, specifically APOE
e4 carriers. These findings have high clinical and public health significance. Moreover,
the results suggest that in this population, a higher dose of PA (amount and/or intensity)
might have greater benefits, but it would be necessary to carry out further studies that
would allow these findings to be contrasted, since the existing evidence is limited. Further
studies should try to establish the optimal dose of PA to effectively and efficiently prevent
CD in APOE e4 carriers.
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